“LLS was very instrumental in helping us connect to Ron Hoffman at Mount Sinai, who is a key opinion leader in myelofibrosis and as we understood from our translational work that could be a very important application for CPI-0610. It was that connection to Ron that really made that come to life and he was the key investigator that generated the early data to give us the confidence to move in the direction that we have gone into so you know we credit a lot of our success to the LLS partnership that we've had over the years.”
Jigar Raythatha, former President & CEO
Constellation Pharmaceuticals
(Quote from Value Creation for Companies through LLS TAP: Dollars & Beyond, December 2020)
Please join The Leukemia & Lymphoma Society's (LLS) Therapy Acceleration Program® (TAP) for a live one-hour discussion panel.
Hear from LLS TAP staff and TAP biotech partners who are pushing boundaries and transforming lives for patients with rare blood cancers.
Agenda:
- Introduction
- Moderated discussion with TAP portfolio partners:
- BioInvent
- Dren Bio
- Immune-Onc Therapeutics
- Kymera Therapeutics
- Q&A
Friday, Jan. 26, 2024
12 noon EST/9 am PST
via Zoom
Register to learn more.
